ArticleCase reports in oncological medicine2026
Synchronous Multicentric Breast Cancer With Opposite Molecular Phenotypes: A Case Report and Therapeutic Considerations.
Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synchronous Multicentric Breast Cancer With Opposite Molecular Phenotypes: A Case Report and Therapeutic Considerations.Case reports in oncological medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multifocal and multicentric breast cancers are increasingly diagnosed due to advances in imaging. Although some degree of molecular heterogeneity between tumor foci is recognized, most multicentric tumors share similar biological profiles. The presence of synchronous multicentric breast cancer with completely opposing molecular phenotypes remains exceptional. Case Presentation: We report the case of a 67-year-old woman diagnosed with synchronous multicentric breast cancer of the left breast. One tumor focus showed a HER2-enriched phenotype (ER-negative, PR-negative, HER2-amplified, and Ki67 60%), whereas a second spatially distinct focus (both confirmed on the surgical specimen) exhibited a luminal A phenotype (ER 100%, PR 1%, HER2-negative, and Ki67 15%). Both lesions were confirmed by magnetic resonance imaging and independently biopsied. The patient underwent modified radical mastectomy and received adjuvant anti-HER2 targeted therapy and endocrine therapy. At 22 months of follow-up, she remains disease-free. Conclusion: This case highlights the importance of comprehensive imaging assessment and independent molecular characterization of all suspicious tumor foci in multicentric breast cancer, as molecular discordance may have significant prognostic and therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.